Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1418253 | PMC |
| http://dx.doi.org/10.1136/bmj.291.6495.602-b | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fertility induction associated with improved peripheral reproductive parameters in male mice subjected to GH and levothyroxine replacement.
Arch Endocrinol Metab
January 2025
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo Laboratório de Hormônios e Genética Molecular LIM/42 Divisão de Endocrinologia São PauloSP Brasil Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Laboratório de Hormônios e Genética Molecular LIM/42 - Divisão de Endocrinologia, São Paulo, SP, Brasil.
Objective: The aim of this study was to characterize the parameters of reproductive anatomy and pituitary hormone expression levels in ames dwarf mice ).
Materials And Methods: Male mice aged 30 days received daily intraperitoneal injections of recombinant human GH and levothyroxine three times weekly for 60 days. The sexual maturation of these animals was compared with that of their wild-type ( ) and untreated ( ) siblings.
Effect of a Low-Molecular-Weight Allosteric Agonist of the Thyroid-Stimulating Hormone Receptor on Basal and Thyroliberin-Stimulated Activity of Thyroid System in Diabetic Rats.
Int J Mol Sci
January 2025
Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St. Petersburg 194223, Russia.
The approaches to correct thyroid deficiency include replacement therapy with thyroid hormones (THs), but such therapy causes a number of side effects. A possible alternative is thyroid-stimulating hormone (TSH) receptor activators, including allosteric agonists. The aim of this work was to study the effect of ethyl-2-(4-(4-(5-amino-6-(-butylcarbamoyl)-2-(methylthio)thieno[2,3-d]pyrimidin-4-yl)phenyl)--1,2,3-triazol-1-yl) acetate (TPY3m), a TSH receptor allosteric agonist developed by us, on basal and thyroliberin (TRH)-stimulated TH levels and the hypothalamic-pituitary-thyroid (HPT) axis in male rats with high-fat diet/low-dose streptozotocin-induced type 2 diabetes mellitus (T2DM).
View Article and Find Full Text PDFTreatment of Primary Hypothyroidism by Slow-Release Liothyronine Monotherapy.
Endocr Metab Immune Disord Drug Targets
January 2025
Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Background: Combination therapy with levothyroxine (L-T4) and slow-release T3 (SRT3) in the treatment of hypothyroidism results in a normal triiodothyronine/thyroxine (T3/T4) ratio above that of L-T4 monotherapy. No clinical study has been reported with SRT3 monotherapy for hypothyroidism.
Methods: This study was conducted in two parts.
Effects of levothyroxine therapy on bone and mineral metabolism in hypothyroidism: a systematic review and meta-analysis.
BMC Endocr Disord
January 2025
The First School of Clinical Medicine, Lanzhou University, No.199 Donggang West Road, Chengguan District, Lanzhou, Gansu Province, 730000, China.
Background: Thyroid hormone plays an important role in accumulating bone development and regulating bone metabolism. It is established that hypothyroidism is linked to increased risk of osteoporosis and fracture. However, the effects of levothyroxine (LT4) treatment on bone for hypothyroid patients remain controversial.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!